LATS1 and cancer: Dysregulation of the hippo pathway has been associated with cancer progression [9–11], including the abnormal expression and activity of yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), and a deficiency in large tumor suppressor kinase 1/2 (LATS1/2) level.